Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Free Cash Flow (2016 - 2026)

Ocular Therapeutix has reported Free Cash Flow over the past 14 years, most recently at -$67.3 million for Q1 2026.

  • For Q1 2026, Free Cash Flow fell 44.45% year-over-year to -$67.3 million; the TTM value through Mar 2026 reached -$226.8 million, down 53.99%, while the annual FY2025 figure was -$206.1 million, 52.86% down from the prior year.
  • Free Cash Flow for Q1 2026 was -$67.3 million at Ocular Therapeutix, down from -$46.3 million in the prior quarter.
  • Over five years, Free Cash Flow peaked at -$8.0 million in Q3 2023 and troughed at -$67.3 million in Q1 2026.
  • A 5-year average of -$31.9 million and a median of -$25.5 million in 2024 define the central range for Free Cash Flow.
  • Biggest five-year swings in Free Cash Flow: surged 45.92% in 2022 and later plummeted 345.98% in 2024.
  • Year by year, Free Cash Flow stood at -$20.2 million in 2022, then grew by 16.61% to -$16.8 million in 2023, then tumbled by 134.38% to -$39.5 million in 2024, then decreased by 17.17% to -$46.3 million in 2025, then crashed by 45.55% to -$67.3 million in 2026.
  • Business Quant data shows Free Cash Flow for OCUL at -$67.3 million in Q1 2026, -$46.3 million in Q4 2025, and -$56.7 million in Q3 2025.